Wall Street analysts forecast that Oscar Health, Inc. (OSCR) will report quarterly loss of -$0.11 per share in its upcoming release, pointing to a year-over-year increase of 79.3%. It is anticipated that revenues will amount to $4.72 billion, exhibiting an increase of 58.1% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Oscar Health metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenue- Premium' should arrive at $4.66 billion. The estimate indicates a year-over-year change of +59.3%.
According to the collective judgment of analysts, 'Revenue- Investment income' should come in at $58.14 million. The estimate suggests a change of +9.3% year over year.
The collective assessment of analysts points to an estimated 'Membership by Offering- Individual and Small Group' of 2.70 million. Compared to the current estimate, the company reported 2.11 million in the same quarter of the previous year.
The average prediction of analysts places 'Medical loss ratio' at 85.1%. Compared to the present estimate, the company reported 88.5% in the same quarter last year.
View all Key Company Metrics for Oscar Health here>>>Shares of Oscar Health have experienced a change of -1.8% in the past month compared to the -0.9% move of the Zacks S&P 500 composite. With a Zacks Rank #1 (Strong Buy), OSCR is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Oscar Health, Inc. (OSCR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).